1610056-01-3

CD4, HIV

Peptide T acts to block viral entry as it inhibits in the MAGI cell assay and blocks infection in the luciferase reporter assay using HIV virions pseudotyped with ADA envelope. Peptide T selectively inhibits HIV replication using chemokine receptor CCR5 compared to CXC4. Peptide T at 10 ^-8 M induces IL-10 production by the human Th2 cell line and PBMC. Also peptide T at 10 ^-9 M concentration significantly inhibits IFN-g production by PBMC.

Peptide T is administered subcutaneously at different doses and phases of the experimental autoimmune encephalomyelitis (EAE) disease, but Peptide T neither prevents nor ameliorates EAE.